an extract from the Australian
It's shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share price rises for companies including Telix Pharmaceuticals, Clarity Pharmaceuticals and earlier-stage PYC Therapeutics.
Dr Storey said he also favoured Neuren Pharmaceuticals, with the share price having come under pressure recently, but he said it had "a terrific asset" which will come into its own over the next 12-18 months.
Neuren's flagship asset is Daybue, a treatment for Rett syndrome which has been licensed to Acadia Pharmaceuticals, and it has a second drug candidate in Phase II development, aiming to treat multiple neurodevelopmental disorders.
Barrenjoey analyst Michelle Benson is also bullish on Neuren, with a $29.30 price target against Friday's $14.73.
Dr Benson's research note on the stock says the company's second-generation asset, NNZ-2591, could present an opportunity four times the scale of Daybue.
(20min delay)